CLIMB BIO INC (CLYM) Forecast, Price Target & Analyst Ratings
NASDAQ:CLYM • US28658R1068
7.28 USD
+0.19 (+2.68%)
At close: Mar 4, 2026
7.28 USD
0 (0%)
After Hours: 3/4/2026, 7:16:14 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CLIMB BIO INC (CLYM).
Forecast Snapshot
Consensus Price Target
$11.66
+ 60.13% Upside
Next Earnings Forecast
Release DateMar 9, 2026
PeriodQ4 / 2025
EPS Estimate-$0.20
Revenue Estimate
ChartMill Buy Consensus
89.23%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$11.66
Upside
+ 60.13%
From current price of $7.28 to mean target of $11.66, Based on 13 analyst forecasts
Low
$8.08
Median
$10.20
High
$24.15
Price Target Revisions
1 Month
20.30%
3 Months
24.22%
Price Target Summary
13 analysts have analysed CLYM and the average price target is 11.66 USD. This implies a price increase of 60.13% is expected in the next year compared to the current price of 7.28.
The average price target has been revised upward by 24.22% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
89.23%
CLYM was analyzed by 13 analysts. The buy percentage consensus is at 89. So analysts seem to be very confident about CLYM.
In the previous month the buy percentage consensus was at a similar level.
CLYM was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-13 | Piper Sandler | Initiate | Overweight |
| 2025-12-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-16 | William Blair | Initiate | Outperform |
| 2025-10-16 | BTIG | Reiterate | Buy -> Buy |
| 2025-10-13 | HC Wainwright & Co. | Initiate | Buy |
| 2025-09-30 | BTIG | Maintains | Buy -> Buy |
| 2025-09-22 | BTIG | Reiterate | Buy -> Buy |
| 2025-08-15 | Baird | Initiate | Outperform |
| 2025-06-06 | Oppenheimer | Initiate | Outperform |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 9, 2026
PeriodQ4 / 2025
EPS Estimate-$0.20
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q-54.68%
Number of Analysts9
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
-2.85%
EPS (3 Months)
-2.68%
Next Earnings Summary
CLYM is expected to report earnings on 3/9/2026. The consensus EPS estimate for the next earnings is -0.2 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A 140.00% | N/A 281.11% | N/A 195.70% | N/A 145.55% | N/A 77.14% | |||||||
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A -12.08% | N/A -20.11% | N/A | N/A | N/A -2.20% | N/A 65.14% | N/A 832.19% | N/A 185.43% | |
| EBIT YoY % growth | -7.45M | -20.93M -180.94% | -35.67M -70.43% | -45.14M -26.55% | -21.466M 52.45% | -27.003M -25.79% | N/A -140.58% | N/A -13.52% | N/A -36.05% | N/A 22.65% | N/A -26.44% | N/A -20.58% | N/A 61.12% | N/A 730.15% | N/A 189.80% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -1.72 73.28% | N/A 22.91% | N/A -20.77% | N/A 48.13% | N/A -4.56% | N/A -26.85% | N/A -20.37% | N/A -13.08% | N/A | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.20 -54.68% | -0.21 30.90% | -0.21 -60.85% | -0.22 -14.08% | -0.22 -11.60% | -0.26 -19.05% | -0.27 -26.83% | -0.28 -27.06% | -0.29 -27.27% |
| Revenue Q2Q % growth | N/A | N/A | N/A | N/A | |||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -15.654M -107.25% | -16.005M 30.47% | -15.759M -47.60% | -16.065M -7.88% | -16.371M -4.58% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
9.48%
EPS Next 5 Year
1.24%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-0.16%
EBIT Next 5 Year
-6.39%
CLIMB BIO INC / CLYM Forecast FAQ
Can you provide the average price target for CLIMB BIO INC stock?
13 analysts have analysed CLYM and the average price target is 11.66 USD. This implies a price increase of 60.13% is expected in the next year compared to the current price of 7.28.
Can you provide the upcoming earnings date for CLIMB BIO INC?
CLIMB BIO INC (CLYM) will report earnings on 2026-03-09, after the market close.
What are the consensus estimates for CLIMB BIO INC (CLYM) next earnings?
The consensus EPS estimate for the next earnings of CLIMB BIO INC (CLYM) is -0.2 USD and the consensus revenue estimate is 0 USD.